Finally, it has been shown that HER+ breast cancer cells treated with SRC inhibitors allowed tumor regression in xenografts and inhibition of proliferation [19] in a p53 dependent manner, suggesting that our results are relevant to other cancer models. The gene discussed is TP53; the disease is neoplasm.